Department of Pharmacy, Namur Research Institute for LIfe Sciences (NARILIS), Namur Thrombosis and Hemostasis Center (NTHC), University of Namur, Namur, Belgium.
Thromb Res. 2013 Sep;132(3):352-9. doi: 10.1016/j.thromres.2013.06.004. Epub 2013 Jun 23.
Early diagnosis of immune heparin-induced thrombocytopenia (HIT) is challenging. HemosIL® AcuStar HIT and heparin-induced multiple electrode aggregometry (HIMEA) were recently proposed as rapid diagnostic methods.
We conducted a study to assess performances of AcuStar HIT-IgG (PF4-H) and AcuStar HIT-Ab (PF4-H). The secondary objective was to compare the performances of the combination of Acustar HIT and HIMEA with standardised clinical diagnosis.
Sera of 104 suspected HIT patients were retrospectively tested with AcuStar HIT. HIMEA was performed on available sera (n=81). The clinical diagnosis was established by analysing in a standardized manner the patient's medical records. These tests were also compared with PF4-Enhanced®, LTA, and SRA in subsets of patients. Thresholds were determined using ROC curve analysis with clinical outcome as reference.
Using the recommended thresholds (1.00AU), the negative predictive value (NPV) of HIT-IgG and HIT-Ab were 100.0% (95% CI: 95.9%-100.0% and 95.7%-100.0%). The positive predictive value (PPV) were 64.3% (95% CI: 35.1%-87.2.2%) and 45.0% (95% CI: 23.2%-68.6%), respectively. Using our thresholds (HIT-IgG: 2.89AU, HIT-Ab: 9.41AU), NPV of HIT-IgG and HIT-Ab were 100.0% (95% CI: 96.0%-100.0% and 96.1%-100.0%). PPV were 75.0% (95% CI: 42.7%-94.5%) and 81.8% (95% CI: 48.3%-97.7%), respectively. Of the 79 patients with a medium-high pretest probability score, 67 were negative using HIT-IgG (PF4-H) test at our thresholds. HIMEA was performed on HIT-IgG positive patients. Using this combination, only one patient on 79 was incorrectly diagnosed.
Acustar HIT showed good performances to exclude the diagnosis of HIT. Combination with HIMEA improves PPV.
早期诊断免疫性肝素诱导的血小板减少症(HIT)具有挑战性。HemosIL® AcuStar HIT 和肝素诱导的多电极聚集检测(HIMEA)最近被提出作为快速诊断方法。
我们进行了一项研究,以评估 AcuStar HIT-IgG(PF4-H)和 AcuStar HIT-Ab(PF4-H)的性能。次要目的是比较 Acustar HIT 和 HIMEA 与标准化临床诊断的性能。
回顾性检测了 104 例疑似 HIT 患者的血清标本,采用 AcuStar HIT 进行检测。对可获得的血清标本(n=81)进行 HIMEA 检测。通过标准化分析患者病历来建立临床诊断。这些检测还与 PF4-Enhanced®、LTA 和 SRA 在部分患者中进行了比较。使用 ROC 曲线分析确定了使用临床结果作为参考的截断值。
使用推荐的截断值(1.00AU),HIT-IgG 和 HIT-Ab 的阴性预测值(NPV)分别为 100.0%(95%CI:95.9%-100.0%和 95.7%-100.0%)。阳性预测值(PPV)分别为 64.3%(95%CI:35.1%-87.2.2%)和 45.0%(95%CI:23.2%-68.6%)。使用我们的截断值(HIT-IgG:2.89AU,HIT-Ab:9.41AU),HIT-IgG 和 HIT-Ab 的 NPV 均为 100.0%(95%CI:96.0%-100.0%和 96.1%-100.0%)。PPV 分别为 75.0%(95%CI:42.7%-94.5%)和 81.8%(95%CI:48.3%-97.7%)。在具有中高度预测试验概率评分的 79 名患者中,有 67 名患者使用 HIT-IgG(PF4-H)检测的结果为阴性,使用我们的截断值。对 HIT-IgG 阳性患者进行 HIMEA 检测。使用这种组合,在 79 名患者中只有 1 名被错误诊断。
AcuStar HIT 对排除 HIT 诊断具有良好的性能。与 HIMEA 联合使用可提高 PPV。